Trois Biotech Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
as on 07-11-2024
- Paid Up Capital ₹ 0.20 M
as on 07-11-2024
- Company Age 4 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -55.75%
(FY 2023)
- Profit -44.19%
(FY 2023)
- Ebitda -47.53%
(FY 2023)
- Net Worth 782.70%
(FY 2023)
- Total Assets -34.89%
(FY 2023)
About Trois Biotech
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.20 M, as per Ministry of Corporate Affairs (MCA) records.
Dhiren Shah, Hiren Doshi, Fredun Medhora, and Three other members serve as directors at the Company.
- CIN/LLPIN
U24100MH2020PTC338789
- Company No.
338789
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Mar 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Trois Biotech?
Board Members(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dhiren Shah  | Director | 13-Mar-2020 | Current |
| Hiren Doshi | Director | 13-Mar-2020 | Current |
| Fredun Medhora | Director | 13-Mar-2020 | Current |
| Dhairya Shah | Director | 13-Mar-2020 | Current |
| Laxman Pawar | Director | 13-Mar-2020 | Current |
| Jinesh Doshi | Director | 13-Mar-2020 | Current |
Financial Performance of Trois Biotech.
Trois Biotech Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 55.75% decrease. The company also saw a substantial fall in profitability, with a 44.19% decrease in profit. The company's net worth Soared by an impressive increase of 782.7%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Trois Biotech?
In 2023, Trois Biotech had a public holding of 50.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sign Pharma Trade Services Private LimitedActive 17 years 2 monthsDhiren Shah and Hiren Doshi are mutual person
Iteeha Hospitality & Entertainment Private LimitedActive 1 year 3 monthsFredun Medhora is a mutual person
Eastern Chemicals (Mumbai) Private LimitedActive 18 years 7 monthsDhiren Shah and Dhairya Shah are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Trois Biotech?
Unlock and access historical data on people associated with Trois Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Trois Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Trois Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
